mRCC: Are we doing all we can to manage adverse events?
11 Feb 2015
mRCC: Are we doing all we can to manage adverse events?
mRCC: Understanding the patient's perspective
mRCC: Closing remarks
Advances in haemato-oncology: Expert panel discussion
Optimizing survival in advanced prostate cancer: Welcome and introduction
Optimizing survival in advanced prostate cancer: Understanding PC heterogeneity to guide treatment choices
Optimizing survival in advanced prostate cancer: Tailoring mCRPC therapies to optimise survival
Optimizing Survival in Advanced Prostate Cancer: Conclusion
The DNA damage response and cancer therapy
UICC 2014 conference report
Comment: SABCS 2014 Highlights
Comment: BOLERO-1 reports HER2-positive breast cancer latest PFS data